EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617)
Value in Health · 2026-06 · 29 (6) · S93
DOI: 10.1016/j.jval.2026.03.455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Sreevalsa Appukkuttan und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Appukkuttan, S., Kalayeh, B., Lee, J., Ngantung, W., & Saeedian, M. (2026). EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617). Value in Health, 29(6), S93. https://doi.org/10.1016/j.jval.2026.03.455
Vancouver
Appukkuttan S, Kalayeh B, Lee J, Ngantung W, Saeedian M. EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617). Value in Health. 2026;29(6):S93. doi:10.1016/j.jval.2026.03.455
BibTeX
@article{Appukkuttan2026,
author = {Appukkuttan, Sreevalsa and Kalayeh, Bashir and Lee, Jean and Ngantung, William and Saeedian, Matia},
title = {EE160 AN ECONOMIC MODEL TO ESTIMATE THE 1-YEAR COSTS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH ENZALUTAMIDE PLUS RADIUM-223 (RA-223) OR LUTETIUM-177 VIPIVOTIDE TETRAXETAN (177LU-PSMA-617)},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S93},
doi = {10.1016/j.jval.2026.03.455}
}
EUVIMED